Cargando…
Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate
Salvage re-irradiation (rRT) for patients with locoregionally recurrent head and neck cancer (rHNC) remains challenging. A retrospective analysis was performed on 49 patients who received rRT between 2011 and 2018. The co-primary endpoint of the study was 2-year freedom from cancer recurrence rate (...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145776/ https://www.ncbi.nlm.nih.gov/pubmed/37109315 http://dx.doi.org/10.3390/jcm12082979 |
_version_ | 1785034418306416640 |
---|---|
author | Mohamad, Issa Abu Hejleh, Taher Abdelqader, Sania Wahbeh, Lina Taqash, Ayat Almousa, Abdelatif Mayta, Ebrahim Al-Ibraheem, Akram Abuhijla, Fawzi Abu-Hijlih, Ramiz Hussein, Tariq Al-Gargaz, Wisam Ghatasheh, Hamza Hosni, Ali |
author_facet | Mohamad, Issa Abu Hejleh, Taher Abdelqader, Sania Wahbeh, Lina Taqash, Ayat Almousa, Abdelatif Mayta, Ebrahim Al-Ibraheem, Akram Abuhijla, Fawzi Abu-Hijlih, Ramiz Hussein, Tariq Al-Gargaz, Wisam Ghatasheh, Hamza Hosni, Ali |
author_sort | Mohamad, Issa |
collection | PubMed |
description | Salvage re-irradiation (rRT) for patients with locoregionally recurrent head and neck cancer (rHNC) remains challenging. A retrospective analysis was performed on 49 patients who received rRT between 2011 and 2018. The co-primary endpoint of the study was 2-year freedom from cancer recurrence rate (FCRR) and overall survival (OS), and secondary endpoints were 2-year disease-free survival (DFS), local failure (LF), regional failure (RF), distant metastases (DM), and RTOG grade 3 ≥ late toxicities. Adjuvant and definitive rRT were delivered to 22 and 27 patients, respectively. A total of 91% of patients were managed with conventional re-RT and 71% of patients received concurrent chemotherapy. The median follow-up after rRT was 30 months. The 2-year FCRR, OS, DFS, LF, RF, and DM were 64%, 51%, 28%, 32%, 9%, and 39% respectively. MVA showed that poor performance status (PS: 1–2 vs. 0) and age > 52 years were predictive of worse OS. In comparison, poor PS (1–2 vs. 0) and total dose of rRT < 60 Gy were predictive of worse DFS. Late RTOG toxicity of grade 3 ≥ was reported in nine (18.3%) patients. FCRR at 2 years after salvage rRT for rHNC was higher than other traditional endpoints and could be an important endpoint to be included in future rRT studies. rRT for rHNC at our cohort was relatively successful, with a manageable level of late severe toxicity. Replacing this approach in other developing countries is a viable option. |
format | Online Article Text |
id | pubmed-10145776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101457762023-04-29 Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate Mohamad, Issa Abu Hejleh, Taher Abdelqader, Sania Wahbeh, Lina Taqash, Ayat Almousa, Abdelatif Mayta, Ebrahim Al-Ibraheem, Akram Abuhijla, Fawzi Abu-Hijlih, Ramiz Hussein, Tariq Al-Gargaz, Wisam Ghatasheh, Hamza Hosni, Ali J Clin Med Article Salvage re-irradiation (rRT) for patients with locoregionally recurrent head and neck cancer (rHNC) remains challenging. A retrospective analysis was performed on 49 patients who received rRT between 2011 and 2018. The co-primary endpoint of the study was 2-year freedom from cancer recurrence rate (FCRR) and overall survival (OS), and secondary endpoints were 2-year disease-free survival (DFS), local failure (LF), regional failure (RF), distant metastases (DM), and RTOG grade 3 ≥ late toxicities. Adjuvant and definitive rRT were delivered to 22 and 27 patients, respectively. A total of 91% of patients were managed with conventional re-RT and 71% of patients received concurrent chemotherapy. The median follow-up after rRT was 30 months. The 2-year FCRR, OS, DFS, LF, RF, and DM were 64%, 51%, 28%, 32%, 9%, and 39% respectively. MVA showed that poor performance status (PS: 1–2 vs. 0) and age > 52 years were predictive of worse OS. In comparison, poor PS (1–2 vs. 0) and total dose of rRT < 60 Gy were predictive of worse DFS. Late RTOG toxicity of grade 3 ≥ was reported in nine (18.3%) patients. FCRR at 2 years after salvage rRT for rHNC was higher than other traditional endpoints and could be an important endpoint to be included in future rRT studies. rRT for rHNC at our cohort was relatively successful, with a manageable level of late severe toxicity. Replacing this approach in other developing countries is a viable option. MDPI 2023-04-19 /pmc/articles/PMC10145776/ /pubmed/37109315 http://dx.doi.org/10.3390/jcm12082979 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mohamad, Issa Abu Hejleh, Taher Abdelqader, Sania Wahbeh, Lina Taqash, Ayat Almousa, Abdelatif Mayta, Ebrahim Al-Ibraheem, Akram Abuhijla, Fawzi Abu-Hijlih, Ramiz Hussein, Tariq Al-Gargaz, Wisam Ghatasheh, Hamza Hosni, Ali Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate |
title | Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate |
title_full | Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate |
title_fullStr | Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate |
title_full_unstemmed | Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate |
title_short | Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate |
title_sort | re-irradiation for recurrent head and neck cancer: freedom from cancer recurrence rate |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145776/ https://www.ncbi.nlm.nih.gov/pubmed/37109315 http://dx.doi.org/10.3390/jcm12082979 |
work_keys_str_mv | AT mohamadissa reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT abuhejlehtaher reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT abdelqadersania reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT wahbehlina reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT taqashayat reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT almousaabdelatif reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT maytaebrahim reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT alibraheemakram reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT abuhijlafawzi reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT abuhijlihramiz reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT husseintariq reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT algargazwisam reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT ghatashehhamza reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate AT hosniali reirradiationforrecurrentheadandneckcancerfreedomfromcancerrecurrencerate |